NCT00274651View on ClinicalTrials.gov

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

PHASE2TerminatedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Cutaneous T-Cell LymphomaPeripheral T-Cell LymphomaNon-Hodgkin's Lymphoma
Interventions
DRUG

belinostat

Trial Locations (15)

10016

NYU Medical Center, New York

10330

King Chulalongkorn Memorial Hospital, Patumwan

31059

Hospital Purpan, Toulouse

33604

Hopitaux du Haut Leveque, Pessac

44195

Cleveland Clinic Foundation, Cleveland

45147

Universitatsklinikum Essen, Essen

49100

Rabin Medical Center, Petah Tikva

66214

Kansas City Cancer Center, Lenexa

77030

MD Anderson Cancer Center, Houston

90110

Songklanagarind Hospital, Prince of Songkla University, Hat Yai

91120

Hadassah University Hospital Ein Kerem, Jerusalem

94305

Leland Stanford Junior University, Stanford

06520

Yale University School of Medicine, New Haven

02115

Dana Farber Cancer Institute, Boston

02118

Boston University Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Valerio Therapeutics

INDUSTRY

NCT00274651 - A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas | Biotech Hunter | Biotech Hunter